Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $73.11

CRISPR Therapeutics AG (NASDAQ:CRSP) has been given an average rating of “Hold” by the twenty-one research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $73.11.

A number of brokerages recently commented on CRSP. Bank of America reduced their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Stifel Nicolaus reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. JMP Securities restated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $42.12 on Thursday. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $75.91. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of -9.64 and a beta of 1.77. The firm has a 50-day simple moving average of $43.06 and a 200-day simple moving average of $45.56.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts forecast that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, Director John Greene bought 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the transaction, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 in the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC boosted its holdings in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Capital International Investors boosted its holdings in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after purchasing an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after purchasing an additional 1,074,238 shares during the last quarter. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of CRISPR Therapeutics by 1.0% in the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after purchasing an additional 23,075 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.